Cargando…

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis

BACKGROUND: The type 1 interferon (IFN) pathway has been identified to potentially affect the response to rituximab (RTX) for rheumatoid arthritis (RA), which suggests the contribution of type 1 IFN pathway genes such as IFN regulatory factor 5 and 7 (IRF5 and IRF7), tyrosine kinase 2 (TYK2), signal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Juge, Pierre-Antoine, Gazal, Steven, Constantin, Arnaud, Mariette, Xavier, Combe, Bernard, Tebib, Jacques, Dougados, Maxime, Sibilia, Jean, Le Loet, Xavier, Dieudé, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640092/ https://www.ncbi.nlm.nih.gov/pubmed/29071117 http://dx.doi.org/10.1136/rmdopen-2017-000448

Ejemplares similares

Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
por: Salmon, J H, et al.
Publicado: (2015)

A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
por: Juge, Pierre‐Antoine, et al.
Publicado: (2022)

Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry
por: Nourisson, Cynthia, et al.
Publicado: (2017)

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients
por: Duarte, Catia, et al.
Publicado: (2021)

Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis
por: Bonnet, Isabelle, et al.
Publicado: (2021)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Predictive value of tender joints compared to synovitis for structural damage in rheumatoid arthritis
por: Cheung, Peter P, et al.
Publicado: (2016)

Lymphoma complicating rheumatoid arthritis: results from a French case–control study
por: Kedra, Joanna, et al.
Publicado: (2021)

Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project
por: van Beers-Tas, Marian H, et al.
Publicado: (2018)

Association between RANK, RANKL and OPG polymorphisms with ACPA and erosions in rheumatoid arthritis: results from a meta-analysis involving three French cohorts
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2016)

Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre
por: Reuter, Katja, et al.
Publicado: (2022)

Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database
por: Juge, Pierre-Antoine, et al.
Publicado: (2023)

Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis
por: Gossec, Laure, et al.
Publicado: (2015)

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study
por: Paulshus Sundlisæter, Nina, et al.
Publicado: (2022)

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis
por: Rausch Osthoff, Anne-Kathrin, et al.
Publicado: (2018)

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients
por: Gossec, Laure, et al.
Publicado: (2019)

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
por: Mariette, Xavier, et al.
Publicado: (2018)

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
por: Nordberg, Lena Bugge, et al.
Publicado: (2018)

Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis
por: Sweeney, Shannon R, et al.
Publicado: (2016)

Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study
por: Flipo, René-Marc, et al.
Publicado: (2017)

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis
por: Mankia, Kulveer, et al.
Publicado: (2021)

Passive smoking in childhood and adulthood and risk of rheumatoid arthritis in women: results from the French E3N cohort study
por: Nguyen, Yann, et al.
Publicado: (2022)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database
por: Seror, Raphaele, et al.
Publicado: (2022)

A new classification of HLA-DRB1 alleles based on acid–base properties of the amino acids located at positions 13, 70 and 71: impact on ACPA status or structural progression, and meta-analysis on 1235 patients with rheumatoid from two cohorts (ESPOIR and EAC cohort)
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2015)

Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire
por: Pollastro, Sabrina, et al.
Publicado: (2019)

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts
por: Bouget, Vincent, et al.
Publicado: (2022)

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, prospective study
por: Alten, Rieke, et al.
Publicado: (2017)

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
por: Matucci-Cerinic, Marco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a0o7mp3bu7bhj9irk2h379u7qa